I hope Eath comes back on to explain to you all the significance of the trial.
It's all to do about
1/where this trial sits in the overall development of a potential vaccine and
2/ the statistical significance of the results (it's power was small because of the small number of participants) .. but that has to do with point 1/)
and
3/ the costs of taking it further.
Listen to what he says about it OK?
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-147
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.80 |
Change
0.000(0.00%) |
Mkt cap ! $74.42M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 206 | $4.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.85 | 1232 | 3 |
View Market Depth
| Last trade - 07.35am 18/07/2025 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable